Pfizer announced on Monday that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has shown promising results in a late-stage clinical trial involving adults aged 18 and older with compromised immune systems.
The study revealed that a single 120 microgram dose of Abrysvo produced a robust immune response, generating strong neutralizing antibodies against both RSV subtypes, RSV-A and RSV-B, across all participant groups. These groups included individuals with lung cancer, end-stage kidney disease, autoimmune inflammatory disorders, and solid organ transplant recipients, all of whom are at higher risk for severe RSV disease.
Abrysvo was well-tolerated by participants, maintaining a safety profile consistent with results from previous studies.
Pfizer plans to submit the trial data to regulatory agencies for further review. Currently, the vaccine is approved for use in individuals aged 60 and older and for pregnant women in the third trimester to protect their infants.
RSV is known for causing cold-like symptoms but is also a major cause of pneumonia in both toddlers and older adults, leading to approximately 177,000 hospitalizations and 14,000 deaths annually in the United States.
